STP705,from Sirnaomics, is a siRNA therapeutic in phase II clinical trialfor the treatment of keloid scars (Table 11).244 STP705 targets both TGF-β1 and COX-2 gene expression with polypeptide nanoparticle-enhanceddelivery.245 The synergistic effect ofsimultaneous silencing TGF-β1 and COX-2 may reverse skin fibrotic scarring by decreasing inflammation andactivating fibroblast apoptosis. Here, PTGS2 is linked to keloid.